/PRNewswire/ -- Theralink Technologies (OTC: OBMP) ("Theralink" or the "Company"), a precision medicine molecular profiling company with a novel...
DENVER, CO / ACCESSWIRE / September 10, 2020 / OncBioMune d/b/a Theralink Technologies (OTC PINK:OBMP) ("Theralink" or the "Company"), a molecular profiling company specializing in patented, biomarker...
Expect to Begin Receiving, Testing and Billing for Patient's Breast Cancer Tumor Specimens in Q4 2020 DENVER, CO / ACCESSWIRE / September 9, 2020 / OncBioMune d/b/a Theralink Technologies (OTC PINK:OBMP),...
DENVER, CO / ACCESSWIRE / September 1, 2020 / OncBioMuned/b/a Theralink Technologies (OTCPINK:OBMP) ("Theralink" or the "Company"), a molecular profiling company specializing in patented, biomarker assay...
DENVER, CO / ACCESSWIRE / August 25, 2020 / OncBioMune d/b/a Theralink Technologies (OTC PINK:OBMP) ("Theralink" or the "Company"), a molecular profiling company specializing in patented, biomarker assay...
Mr. Fanelli joins the Theralink® team having previously held positions at Metabolon Inc., Core Diagnostics, Nanostring Technologies and Bio-Rad Laboratories DENVER, CO / ACCESSWIRE / July 22, 2020 / OncBioMune...
The Theralink ® assay may have significant value for triple-negative breast cancer patients
GOLDEN, CO / ACCESSWIRE /Â June 17, 2020 / OncBioMune (OTC PINK:OBMP) d/b/a Theralink Technologies, a molecular profiling company, today announced the launch of its new, user-friendly corporate website,...
GOLDEN, CO / ACCESSWIRE / June 10, 2020 / OncBioMune Pharmaceuticals, Inc. (OTC PINK:OBMP) ("OncBioMune") today announced the appointment of Mick Ruxin, M.D. as President & CEO and Mr. Jeffrey Busch as...
Avant Diagnostics provides personalized medicine data for physicians and measures the activation state of key drug targets and signaling pathways for Biopharmas through its Theralink® assays